Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2024; 16(9): 3820-3831
Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.3820
Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.3820
Roles of the tumor microenvironment in the resistance to programmed cell death protein 1 inhibitors in patients with gastric cancer
Ren-Jie Xia, Xiao-Yu Du, Jian-Guo Ma, Shu-Mei Xu, Rui-Fang Fan, Jian-Wei Qin, Long Yan, Department of General Surgery, The 940th Hospital of Joint Logistic Support Force of Chinese People’s Liberation Army, Lanzhou 730050, Gansu Province, China
Ren-Jie Xia, Xiao-Yu Du, Department of Medicine, Northwest Minzu University, Lanzhou 730050, Gansu Province, China
Li-Wen Shen, Department of Medical Support Center, The 940th Hospital of Joint Logistic Support Force of Chinese People’s Liberation Army, Lanzhou 730050, Gansu Province, China
Co-first authors: Ren-Jie Xia and Xiao-Yu Du.
Co-corresponding authors: Jian-Wei Qin and Long Yan.
Author contributions: Xia RJ, Du XY, and Shen LW contributed equally to this work; Xia RJ and Du XY designed the research study; Xia RJ and Shen LW conducted the literature review, drafted the original manuscript; Ma JG and Xu SM assisted in writing part of the manuscript; Fan RF made critical revisions of manuscript; Qin JW and Yan L offered guidance and assisted as the corresponding authors; and all authors prepared the draft and approved final manuscript.
Supported by the Natural Science Foundation of Gansu Province , No. 21JR1RA186 ; and the Health Industry Research Program of Gansu Province , No. GSWSKY2021-043 .
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Long Yan, MD, Associate Chief Physician, Department of General Surgery, The 940th Hospital of Joint Logistic Support Force of Chinese People’s Liberation Army, No. 333 Nanbinhe Middle Road, Qilihe District, Lanzhou 730050, Gansu Province, China. lzzy940@163.com
Received: March 21, 2024
Revised: May 27, 2024
Accepted: August 9, 2024
Published online: September 15, 2024
Processing time: 171 Days and 21.2 Hours
Revised: May 27, 2024
Accepted: August 9, 2024
Published online: September 15, 2024
Processing time: 171 Days and 21.2 Hours
Core Tip
Core Tip: The discovery of immunotherapy has changed the management of patients with gastric cancer (GC). Programmed cell death protein 1 (PD-1) inhibitors are revolutionary drugs for the therapeutic approach of GC, but resistance to PD-1 inhibitors often occurs in patients with GC. We herein discuss the effects of the tumor microenvironment on the resistance to PD-1 inhibitors in GC patients, aiming to reduce this resistance in the future.